A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

This study is testing an experimental drug called ACT001 to see if it can safely help children and young adults fighting aggressive brain tumors like DIPG. Researchers are looking for new ways to stop these tumors from growing when standard treatments haven't worked or when the disease has returned.

This trial is for patients aged 1 to 39 who have been diagnosed with DIPG or specific high-grade brain tumors with a genetic change called H3K27. Participants must meet certain timing requirements regarding their previous radiation, surgery, or other cancer treatments.

Participants will receive the experimental drug ACT001 to see how well it works and if it is safe to take. Doctors will monitor participants closely to check their health and see how the tumor responds to the new treatment.

The study is currently recruiting patients at medical centers in Aurora, Colorado; Washington D.C.; and Miami, Florida. Because this is a clinical trial, you would work closely with your medical team to see if this is the right next step for your specific situation.